UBTF tandem duplications define a distinct ...
Document type :
Compte-rendu et recension critique d'ouvrage
Permalink :
Title :
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
Author(s) :
Duployez, Nicolas [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Service de pathologie [CHU Lille]
Vasseur, Loïc [Auteur]
Génomes, biologie cellulaire et thérapeutiques [GenCellDis (U944 / UMR7212)]
Kim, Rathana [Auteur]
Largeaud, Laëtitia [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Université Toulouse III - Paul Sabatier [UT3]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Passet, Marie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
L’haridon, Anaïs [Auteur]
Lemaire, Pierre [Auteur]
Fenwarth, Laurène [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Geffroy, Sandrine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Helevaut, Nathalie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Adès, Lionel [Auteur]
Université Paris Cité [UPCité]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lebon, Delphine [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
CHU Amiens-Picardie
Berthon, Céline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Marceau-Renaut, Alice [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Cheok, Meyling [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Lambert, Juliette [Auteur]
Thérapie génique et contrôle de l'expansion cellulaire [UMR E007]
Récher, Christian [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Raffoux, Emmanuel [Auteur]
Micol, Jean-Baptiste [Auteur]
Département d'hématologie [Gustave Roussy]
Pigneux, Arnaud [Auteur]
Gardin, Claude [Auteur]
Delabesse, Eric [Auteur]
Soulier, Jean [Auteur]
Hunault, Mathilde [Auteur]
Dombret, Hervé [Auteur]
Itzykson, Raphael [Auteur]
Clappier, Emmanuelle [Auteur]
Preudhomme, Claude [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Service de pathologie [CHU Lille]
Vasseur, Loïc [Auteur]
Génomes, biologie cellulaire et thérapeutiques [GenCellDis (U944 / UMR7212)]
Kim, Rathana [Auteur]
Largeaud, Laëtitia [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Université Toulouse III - Paul Sabatier [UT3]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Passet, Marie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
L’haridon, Anaïs [Auteur]
Lemaire, Pierre [Auteur]
Fenwarth, Laurène [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Geffroy, Sandrine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Helevaut, Nathalie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Adès, Lionel [Auteur]
Université Paris Cité [UPCité]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lebon, Delphine [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
CHU Amiens-Picardie
Berthon, Céline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Marceau-Renaut, Alice [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Cheok, Meyling [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Lambert, Juliette [Auteur]
Thérapie génique et contrôle de l'expansion cellulaire [UMR E007]
Récher, Christian [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Raffoux, Emmanuel [Auteur]
Micol, Jean-Baptiste [Auteur]
Département d'hématologie [Gustave Roussy]
Pigneux, Arnaud [Auteur]
Gardin, Claude [Auteur]
Delabesse, Eric [Auteur]
Soulier, Jean [Auteur]
Hunault, Mathilde [Auteur]
Dombret, Hervé [Auteur]
Itzykson, Raphael [Auteur]
Clappier, Emmanuelle [Auteur]
Preudhomme, Claude [Auteur]

Journal title :
Leukemia
Publisher :
Springer Nature
Publication date :
2023-04
ISSN :
0887-6924
HAL domain(s) :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
English abstract : [en]
Abstract Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF ...
Show more >Abstract Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF -TDs occur in about 3% of patients aged 18–60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF -TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1 mutations (61%), FLT3 -ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3 -ITD. UBTF -TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF -wild-type patients. In patients enrolled in the ALFA-0702 study ( n = 614 patients including 21 with UBTF -TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF -TD patients were 42.9% (95%CI: 23.4–78.5%) and 57.1% (95%CI: 39.5–82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1 -mutated clones are frequently selected under ICT. This study supports the recognition of UBTF -TD AML as a new AML entity in adults.Show less >
Show more >Abstract Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF -TDs occur in about 3% of patients aged 18–60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF -TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1 mutations (61%), FLT3 -ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3 -ITD. UBTF -TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF -wild-type patients. In patients enrolled in the ALFA-0702 study ( n = 614 patients including 21 with UBTF -TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF -TD patients were 42.9% (95%CI: 23.4–78.5%) and 57.1% (95%CI: 39.5–82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1 -mutated clones are frequently selected under ICT. This study supports the recognition of UBTF -TD AML as a new AML entity in adults.Show less >
Language :
Anglais
Popular science :
Non
Source :
Submission date :
2024-02-17T03:33:01Z
Files
- s41375-023-01906-z.pdf
- Open access
- Access the document